Semax vs PE-22-28
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: SEMAX, Heptapeptide SEMAX
A synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Approved in Russia for stroke and cognitive enhancement. Known for nootropic and neuroprotective effects.
Also: PE22-28, Spadin Analog
A synthetic heptapeptide (7 amino acids) derived from Spadin, a naturally occurring antidepressant peptide. PE-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of Spadin. Works by blocking TREK-1 potassium channels in the brain.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- Semax has stronger research evidence (Human Trials) compared to PE-22-28 (Animal Studies).
Detailed Comparison
| Attribute | Semax | PE-22-28 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semax increases BDNF and NGF expression, modulates dopamine and serotonin systems, and has anti-inflammatory effects in the brain. It enhances neuroplasticity and protects neurons from oxidative stress and excitotoxicity. | PE-22-28 selectively blocks TREK-1 (TWIK-related potassium channel 1), a two-pore domain potassium channel highly expressed in the brain. TREK-1 inhibition increases neuronal excitability and enhances serotonergic and noradrenergic neurotransmission. This mechanism is distinct from traditional SSRIs and produces rapid-onset antidepressant effects in preclinical studies. |
| Common Dosing | 200-600 mcg intranasal daily 1-3x daily, intranasal | 100-300 mcg intranasal or subcutaneous Once daily |
| Administration | Intranasal spray (most common) | Intranasal or subcutaneous injection |
| Typical Duration | 10-30 days typical | Research protocols vary, often 2-4 weeks |
| Best Time to Take | Morning or early afternoon | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Russian research shows cognitive enhancement, improved memory and attention, and benefits for stroke recovery. Studies demonstrate increased BDNF levels and neuroprotective effects. Used clinically in Russia for stroke, TBI, and cognitive disorders. | Animal studies demonstrate significant antidepressant and anxiolytic effects within days of administration (faster than traditional SSRIs which take weeks). PE-22-28 shows improved stability compared to full Spadin while maintaining efficacy. Research indicates potential for treatment-resistant depression. No human clinical trials conducted yet. |
Frequently Asked Questions: Semax vs PE-22-28
What is the difference between Semax and PE-22-28?
Semax is a cognitive peptide that a synthetic peptide derived from acth (4-10) fragment with added pro-gly-pro sequence. approved in russia for stroke and cognitive enhancement. known for nootropic and neuroprotective effects. PE-22-28 is a cognitive peptide that a synthetic heptapeptide (7 amino acids) derived from spadin, a naturally occurring antidepressant peptide. pe-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of spadin. works by blocking trek-1 potassium channels in the brain. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semax or PE-22-28?
Neither is universally "better" - the choice depends on your specific goals. Semax is typically used for cognitive purposes, while PE-22-28 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semax and PE-22-28 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semax and PE-22-28 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.